Kevin Xu

Most people who run a contract research organization spent their careers inside one. Kevin Xu did the opposite. For more than fifteen years he sat at Goldman Sachs, building and running the firm's Asia-Pacific Healthcare and Life Sciences investing practice, the team that decided which biotech, pharma, medtech, and digital-health bets the bank would back. He joined ClinChoice the way bankers usually do: as money, then as a board director. Then he took the title that bankers usually never do. Chairman and CEO.

ClinChoice is the kind of company patients never see and never forget to depend on. It is a full-service CRO, the outsourced engine that pharmaceutical and biotech companies hire to actually run their clinical trials, manage the data, satisfy the regulators, and shepherd a molecule from a promising idea to an approved therapy. The company traces its roots back roughly three decades to Fountain Medical Development, the operation that rebranded as ClinChoice Inc. in 2020. Today it employs around 4,000 people, operates in more than fifteen countries across North America, Europe, and the Indo/Asia-Pacific region, and has delivered north of 3,000 studies. Its therapeutic muscle sits in oncology and hematology, immunology and inflammation, cardiometabolics, and central nervous system disorders.

Xu's route into that chair is the interesting part. He did not start in finance at all. His first degrees were in the brain: a B.S. from the University of Maryland, then a master's in Neuroscience and Clinical Psychology from King's College London. Only after that did he pick up a Master of Finance at the University of Cambridge, between 2008 and 2010. So the person now running one of pharma's quieter workhorses understands the science the trials are testing, the psychology of the patients in them, and the math of the capital that pays for it all. That is a rare three-sided fluency.

The Goldman years

At Goldman, Xu spent over eighteen years in corporate finance, with the bulk of it leading healthcare and life sciences investing across the Asia Pacific. He worked out of Hong Kong and, earlier, Stamford, Connecticut. The mandate was broad on purpose: pharma, biotech, medical devices, outsourcing services like CROs and CDMOs, consumer health, and the newer wave of AI-driven health companies. Leading that kind of book teaches you what separates a company that scales from one that stalls. It is rarely the science alone. It is operations, regulatory discipline, and the unglamorous ability to deliver a trial on time, on budget, and clean enough that a regulator signs off.

ClinChoice was one of the companies he backed. Goldman appears among the company's investors, and Xu joined its board around 2019, the year before the rebrand. In 2022 the company raised a $150 million Series E. Somewhere along that arc the relationship deepened from check-writer to steward, and Xu stepped fully across the table to run the place he had helped capitalize.

What he is building now

Xu's thesis for ClinChoice is plain in the moves he makes: drug development is too slow and too siloed, and the fix runs through partnerships that connect academic research to commercial-grade execution. In March 2026, ClinChoice announced a strategic partnership with Monash University to fast-track early-phase clinical trials, pairing the university's research and clinical infrastructure with ClinChoice's global development, regulatory, and data-science capabilities. "We are honored to formalize this partnership with Monash University, a globally respected institution at the forefront of pharmaceutical science," Xu said at the time, framing it as "a strong testament to ClinChoice's mission to support innovation through academic and clinical partnerships."

It is a tell. An operator obsessed with internal metrics talks about throughput. Xu talks about who he is partnering with and why. The academic-to-clinic bridge is the same idea, applied repeatedly: get the good science out of the lab and into a trial faster, with fewer dropped handoffs in between.

The parts that do not fit the suit

For someone whose CV reads like a stack of credentials, Xu keeps a few things that refuse to behave. He still works with NGOs and government centers to advance mental-health awareness and destigmatize psychological illness, a thread that connects straight back to those early King's College years studying clinical psychology. It is not a press-release cause for him; it predates the C-suite. And then there is the wake-surfing. A CRO chief executive who lists wake-surfing among his pursuits is not following anyone's playbook for how a pharma boss is supposed to spend a Saturday.

He also stays loyal to the institutions that shaped him. Xu serves as the Queens' Alumni Ambassador for Strategic Partnerships at the University of Cambridge, the same university where he learned the finance half of his toolkit, and beyond ClinChoice he holds board seats at Zhenge Biotech and Puyi Biotechnology, keeping a hand in the investor's game even as he runs an operating company.

Put it together and you get an unusual profile for the top of a clinical research organization: a scientist by training, a psychologist by curiosity, a financier by trade, and an operator by choice. The companies he used to fund had to convince him they could execute. Now he is the one who has to deliver. He spent a career learning what good looks like from the outside. The interesting question is what he does with that knowledge from the inside.